
ReNerve LTD

ASX:RNV

Transforming Nerve Repair Through Science

Q1 FY27 Quarterly Update & Financial Highlights

ReNerve Company presentation |
Quarterly webinar | November 2026



Important Notice & Disclaimer

ReNerve LTD

Nature of Document: This presentation has been prepared and issued by ReNerve Ltd (Company) to provide general information about the Company. The information in this document is in summary form and should not be relied upon as a complete and accurate representation of any matters that a reader should consider in evaluating the Company. While management has taken every effort to ensure the accuracy of the material in this presentation, the Company have not verified the accuracy or completeness of the material contained in this presentation.

Not an offer: this presentation should not be distributed, transmitted, or viewed by any person in any jurisdiction where the distribution, transmission or viewing of this document would be unlawful under the securities or other laws of that or any other jurisdiction.

Not financial product advice: You should not act and should refrain from acting in reliance on this presentation. Nothing contained in this presentation constitutes investment, legal, tax or other advice. This presentation does not take into account the individual investment objectives, financial situation and particular needs of potential investors. Before making a decision to invest in the Company at any time, you should conduct, with the assistance of your broker or other financial or professional adviser, your own investigation in light of your particular investment needs, objectives and financial circumstances and perform your own analysis of the Company before making any investment decision.

Forward looking statements: This presentation contains forward-looking information about the Company and its operations. In certain cases, forward-looking information may be identified by such terms as "anticipates", "believes", “should”, "could", "estimates", “target”, “likely”, “plan”, "expects", "may", “intend”, "shall", "will", or "would". These statements are based on information currently available to the Company and the Company provides no assurance that actual results will meet management's expectations. Forward-looking statements are subject to risk factors associated with the Company’s business, many of which are beyond the control of the Company. It is believed that the expectations reflected in these statements are reasonable but they may be affected by a variety of variables and changes in underlying assumptions which could cause actual results or trends to differ materially from those expressed or implied in such statements. There can be no assurance that actual outcomes will not differ materially from these statements.

Disclaimer: No representation or warranty, express or implied, is made by the Company that the material contained in this presentation will be achieved or proved correct. Except for statutory liability which cannot be excluded, the Company, its directors, officers, and employees expressly disclaim any responsibility for the accuracy, fairness, sufficiency or completeness of the material contained in this presentation and excludes all liability whatsoever (including in negligence) for any loss or damage which may be suffered by any person as a consequence of any information in this presentation or any effort or omission therefrom. The Company will not update or keep current the information contained in this presentation or to correct any inaccuracy or omission which may become apparent, or to furnish any person with any further information. Any opinions expressed in the presentation are subject to change without notice. More information can be obtained at the company website renerve.com.au .

ReNerve Ltd ABN 23 614 848 216

Executive Summary



Development of Novel Nerve Repair & Regeneration Products

ReNerve is developing a comprehensive portfolio of products for the nerve repair and regeneration markets and related surgical procedures, with clearly defined commercial position and demand.

Expanding Product Portfolio

3 product ranges in the US market with the nerve conduit range next (commercial manufacturing 1H CY27)

Strong Sales & Distribution Presence

ReNerve has established logistics, warehouse and invoicing infrastructure with a strong focus on building a sales distribution network for all products in the US.

Global Expansion & Commercialisation

Successful ongoing expansion since the November 2024 ASX listing into Ex-US markets in Asia, India, The Middle East, and The Americas.

Clinical & Professional Validation

Improved patient outcomes for post-surgical measures of pain and surgery satisfaction, as well as proven ease of use for surgeons.

Quarter highlights



Record quarterly sales of $584k – the Company's strongest sales quarter to date

$584k

Record quarterly sales

Strongest quarter to date

+774%

vs corresponding quarter

Q1 FY26 → Q1 FY27

+176%

vs previous quarter

Q4 FY26 → Q1 FY27

>$200k

September sales

First month above $200k

Quarterly sales exceeded the FY26 full-year result

Sales in a single quarter now surpass the whole of 2025/26, reflecting the impact of multiple product ranges in market and direct US salespeople.

Cash of ~$1.62M at 30 September 2026

Following the initial drawdown under the up to $5M RiverFort convertible note facility signed in July. Net operating cash outflow of $1.11M in the quarter.

4.5 quarters of funding available, including the $3.4M undrawn facility (Appendix 4C)


Quarterly sales growth

From A$24K to A$584K in three years | Jul–Sep 2023 to Jul–Sep 2026

24x growth since Jul–Sep 2023

+176% vs previous quarter (Apr–Jun 2026)

8.7x vs same quarter last year




Source: ReNerve quarterly activities reports and Appendix 4C; company sales data. FY26 sales of A$510k; Q1 FY27 A$584k.

What drove the quarter



Product expansion and direct US sales lifted both sales and cash receipts

Sales vs cash receipts from customers (A$k)




Key revenue drivers

- 25 US distributors (21 at the December 2025 quarter)
- 2 direct US salespeople now in market
- 100+ US hospital approvals across the product range
- September was the first month above $200k sales, setting a strong run-rate cadence.
- September sales mostly repeat orders
- 5 new hospital approvals in September

Source: ReNerve quarterly activities reports and Appendix 4C (Q1 FY26–Q1 FY27); AGM presentation (October 2026). Sales mix to be provided by management.

Financial Snapshot

Q1 FY27 (quarter ended 30 September 2026)



Source: ReNerve quarterly activities reports and Appendix 4C. Q1 FY27 sales up 774% on Q1 FY26 and 176% on Q4 FY26, as reported.

Cash position

A$1.62M

at 30 Sep 2026 (A$1.488M at 30 Jun 2026)

Funding runway at 30 September 2026 (A$M)

Cash and cash equivalents	1.62
Undrawn RiverFort facility	3.40
Total available funding	**5.02**
Q1 FY27 net operating cash outflow	(1.11)
Quarters of funding incl. facility (Appendix 4C)	**4.5**

Further drawdowns require mutual agreement and facility conditions. Each drawdown matures after 18 months, with monthly cash repayments from month 6; convertible at a 30% premium to the 5-day VWAP (10.0849c for the first drawdown); secured over all assets, incl. R&D Tax Incentive proceeds.

Key achievements



Commercial, funding and research milestones delivered in the quarter

Asia-Pacific expansion

- Indonesia marketing approval for the NervAlign® Nerve Cuff (July)
- First NervAlign® Nerve Cuff cases completed in Hong Kong and Malaysia (September)
- Indonesia: population of 280M+, large trauma and diabetes-related need

Funded for growth

- Up to A$5M RiverFort convertible note facility, 3-year availability
- Initial drawdown of ~A$1.6M face value (~A$1.361M net)
- Secured over present and after-acquired property, including future R&D Tax Incentive proceeds

RMIT research partnership

- A$499k Australian Government-funded project (AEA Launch Program, Ignite Round 2)
- Developing a gel from a patient's own blood to accelerate nerve regeneration after prostate surgery
- Early-stage R&D; potential application across cuffs, wraps, conduits and Nerve Guide Matrix

Sales engine delivering

- Multiple product ranges in market driving record sales
- Direct salespeople and 25 US distributors; marketing efforts in Asia
- Additional products coming to market to build on growth

The “Align” Study

Clinical Study on the NervAlign® Nerve Cuff

Definitive randomised study following surgical neurolysis (nerve repair) to show the benefit of protecting the nerve after repair surgery.

Study Design: two parallel cohorts, ~120 patients each

- Control Group: standard-of-care nerve repair
- Test Group: nerve repair protected with the NervAlign® Nerve Cuff
- Builds on the interim comparative study shown at right (ACFAS, March 2025)


Key Outcomes:

- Primary: significance in pain reduction (pre- vs post-operative pain score)
  - Secondary outcomes in patient recovery
  - Product performance in surgery
- Patient follow-up around 6 to 9 months

Data presentation

- Recruitment nearly complete
- Data accumulated along the way
- Preliminary data to be presented at ACFAS, March 2027
- Full data expected to be published and presented in 2027

Interim study: pre- vs post-surgery pain score



Interim data (ACFAS, Mar-25), not “Align” results: n=13 Nerve Cuff vs n=10 standard of care; p=0.021

Catalysts FY27



- Scale US sales via direct reps and 25 distributors, building on record Q1 FY27 sales
- Asia-Pacific: Singapore approval (1H –'27); first Hong Kong and Malaysia cases (Sep-26)
- Complete "Align" study recruitment (nearly complete); preliminary data at ACFAS, March 2027
- European approval submission utilising "Align" study data – aiming for CY27
- Nerve conduit range: commercial manufacturing in 1H CY27, followed by first market launch
- Nerve Guide Matrix: complete Stage 3 of 4 (1Qtr CY'27), then GMP manufacturing (Stage 4)
- Empliq growth, with additional supply partners to support availability as sales scale

Value drivers for the next 12–24 months

Driving sales and new products into market

FY27 focus: scaling sales and launching the nerve conduit range

Empliq products ranges now in the US market

- Complements the nerve products sales
- Anticipating faster sales growth through multiple products
- Additional supply partners to ensure product availability as sales grow

Continue to expand into Ex-US markets

- Establishing partners Ex-USA
- Initial product launches across India and Asia
- Follow on with new products, the first being the nerve conduit

Working with distributors for additional approvals

- Direct sales team in the US having an impact on sales growth
- Increasing hospital approvals, now over 100
- Rising sales with multiple product ranges in market

Ongoing Clinical Study

- Positive interim data (Mar-25; p=0.021)
- "Align": ~120 patients per cohort
- Recruitment nearly complete
- Preliminary data: ACFAS, Mar-27

Investment Highlights

ReNerve LTD



In Market Products

Nerve Cuff transitioned from R&D to commercial sales with 3 product lines in market and nerve conduits coming.



Immediate Market Need

Products promote nerve injury recovery and wound repair leading to faster patient recovery and better outcomes.



Growing Market

Nerve repair biomaterials & related markets are forecast to grow by >17% pa, estimated to be worth >**US$6.19Bn by 2031. USD$1Bn+ market for human tissue product ranges**[1].



Diverse Product Portfolio

3 product ranges in market; nerve conduit range moving to commercial manufacturing in 1H CY27, with more under development.



Growing Distribution

25 US distributors, direct sales reps and 100+ hospital approvals; expanding across Asia-Pacific.



Board & Management

Founded by a neurosurgeon and medtech researchers; the team has taken the FDA-cleared NervAlign® Nerve Cuff from R&D to commercial sales.

[1] Global Nerve Repair Biomaterials Market Research Report (2020–2031). Dermal and amniotic: MarketWide Research, Dermal and Amniotic Tissue Market Report 2025–2032 (2025).


ReNerve[LTD]

Appendix



Company Portfolio

ReNerve LTD



Product Development Pipeline

ReNerve LTD


Nerve conduit range

- Nerve Conduit and protector ranges
  - Completed initial manufacturing ‘test run’
  - Progressing to commercial manufacturing in 1H CY27
  - 3 types of conduits to come to market



Nerve guide matrix

- In commercial development Stage 3 of 4
- FDA approval pathway confirmed
- Next step: GMP and commercial manufacturing
- Strong 12-month preclinical data shows the product works in both sensory and motor nerves




Target Market

The Global Nerve Repair Biomaterials Market was valued at US$1.6Bn in 2024 and is projected to grow at a 17.8% CAGR to US$6.19Bn by 2031.[1]

Our Target Markets

- **Global Nerve Repair Biomaterial Market**
- **Dermal and Amniotic Tissue** *Surgical Applications (Trauma, plastic surgery)*
- **Dermal and Amniotic Tissue** *Orthopedics (Tendon and Ligament)*



[1] Global Nerve Repair Biomaterials Market Research Report (2020–2031). Dermal and amniotic: MarketWide Research, Dermal and Amniotic Tissue Market Report 2025–2032 (2025).

Sales and Marketing Update



US Market Expanded Distribution Channels

Robust Portfolio

- Expanded to 25 distributors across the US
- Full logistics, warehousing and invoicing in place
- Distributors can sell the entire ReNerve product range
- Will add additional distributors to the network as products come to market

Focus surgical areas Subspecialties

- Hand (upper extremity)
- Breast
- Lower Extremity (M.D. & DPM)
- Plastics Reconstruction
- Head & Neck
- Spine

Asia

ReNerve LTD

India


- Significant opportunity
- Existing distribution partner in place
- First product shipment underway for initial cases

Malaysia

- Clear target customer group
- First implants completed
- Use as a regional distribution hub

Indonesia

- In discussion with local distribution partners
- Focus on private hospital systems
- Direct engagement with surgeons and hospitals now active



Hong Kong

- Strong local partner
- Received 1st repeat order
- Now engaging with the broader local market

Philippines

- Complements rest of Asia strategy
- Will focus on key private hospital systems

Thailand

- Focus on private hospitals
- Looking to partner with local distributors

NervAlign®

Nerve Cuff



ReNerve LTD

Key Features

1 Product

- Protects nerves during recovery post peripheral nerve repair
- Great handling characteristics and absorbed within 6 months

2 Patient Benefit

- Bio-absorbed within six months.
- Produced using a non-toxic method.
- Terminally sterilised with no residual chemicals.
- Covered under procedural reimbursement rather than individual product reimbursement.
- Promotes revascularisation and remodelling.
- Semi-translucent

3 Surgeon Benefit

- Requires no change to surgical technique or procedures.
- Available in various sizes with ability to be trimmed to required shape.
- Pliable, conformable, semi-translucent and easy to use.



ReNerve LTD

ReNerve's "Align" Clinical Study

Patient Results

- Definitive clinical study on using NervAlign Nerve Cuff for nerve repair
- 120 patients per cohort;
- Comparing standard of care vs treatment with NervAlign Nerve Cuff

Clinical Use

- Hundreds of patients implanted to date
- Received positive feedback from surgeons stating it handles well, is pliable and conforms and has resulted in strong patient outcomes.
- Positive surgeon feedback when used with attachment methods including sutures, glue, micro clips and 'nothing'.

Empliq™

Product Range









ReNerve LTD

Empliq Product Portfolio









	Empliq AmnioLite	Empliq AmnioDuo	Empliq Placental	Empliq Dermal
Description	Single-layer amniotic membrane allograft	Double-layer amniotic membrane allograft	Placental allograft including amniotic membrane and chorion	Deep-layer dermal matrix
Clinical Value	Natural barrier to protect wounds from external environment	Thicker barrier for complex wounds Improved handling characteristics	Natural barrier to protect wounds from external environment Additional structural support	Natural scaffold for protection, reinforcement and capillary formation No basement membrane - rapid tissue ingrowth and healing
Potential Applications	DFUs, VLUs, surgical wounds, vulnerable tissue	DFUs, VLUs, pressure injury, surgical wounds		Breast reconstruction, Tendon augmentation, abdominal wall repair, hernia repair

Contact Us

ReNerve Limited

+61 (03) 9482 3940

info@renerve.com.au

Level 10/99 Queen St, Melbourne, Victoria 3000 Australia

Follow us on socials!

